Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19
暂无分享,去创建一个
O. Elemento | L. Ivashkiv | R. Schwartz | B. tenOever | F. Barrat | Benjamin E. Nilsson-Payant | Y. Bram | L. Carrau | André F. Rendeiro | Vasuretha Chandar | Chao Yang | Paôline Laurent | A. F. Rendeiro | P. Laurent | A. Rendeiro
[1] L. Ivashkiv,et al. CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes , 2022, Nature Communications.
[2] L. Ivashkiv,et al. Chemokines form nanoparticles with DNA and can superinduce TLR-driven immune inflammation , 2022, The Journal of experimental medicine.
[3] Shondra M. Pruett-Miller,et al. ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection , 2022, Science Immunology.
[4] O. Elemento,et al. Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy , 2022, iScience.
[5] J. Lieberman,et al. Inflammasome activation in infected macrophages drives COVID-19 pathology , 2021, Nature.
[6] M. Merad,et al. The immunology and immunopathology of COVID-19 , 2022, Science.
[7] L. Kristensen,et al. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection , 2022, The EMBO journal.
[8] Si Ming Man,et al. Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway , 2022, Immunity.
[9] Vivek V. Thacker,et al. The cGAS–STING pathway drives type I IFN immunopathology in COVID-19 , 2022, Nature.
[10] S. Sugita,et al. Extensive mucosal sloughing of the small intestine and colon in a patient with severe COVID‐19 , 2021, DEN open.
[11] F. Voltarelli,et al. The relationship between COVID‐19 viral load and disease severity: A systematic review , 2021, Immunity, inflammation and disease.
[12] A. Tall,et al. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein , 2021, Scientific Reports.
[13] Fabian J Theis,et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis , 2021, Cell.
[14] O. Elemento,et al. The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication , 2021, Journal of virology.
[15] R. Nussbaum,et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 , 2021, Science immunology.
[16] Mark S. Anderson,et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths , 2021, Science Immunology.
[17] J. Casanova,et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs , 2021, The Journal of experimental medicine.
[18] Jianguo Wu,et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation , 2021, Nature Communications.
[19] Michael A. Smith,et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus , 2021, Science Translational Medicine.
[20] L. Dölken,et al. Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned , 2021, Viruses.
[21] J. Schultze. Deutsche COVID-19 Omics Initiative (DeCOI) , 2021, BIOspektrum.
[22] Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. , 2021, Nature cell biology.
[23] Timothy L. Tickle,et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets , 2021, Nature.
[24] André F. Rendeiro,et al. A molecular single-cell lung atlas of lethal COVID-19 , 2021, Nature.
[25] E. Coccia,et al. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection , 2021, bioRxiv.
[26] C. Garlanda,et al. SARS-CoV-2–associated ssRNAs activate inflammation and immunity via TLR7/8 , 2021, bioRxiv.
[27] Yufeng Shen,et al. Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells , 2021, Science Immunology.
[28] André F. Rendeiro,et al. The spatial landscape of lung pathology during COVID-19 progression , 2021, Nature.
[29] J. Casanova,et al. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. , 2021, Comptes rendus biologies.
[30] F. Bazzoli,et al. Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study , 2021, BMJ open gastroenterology.
[31] J. Casanova,et al. SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4 , 2021, The Journal of experimental medicine.
[32] A. Maghazachi,et al. Chemokines and chemokine receptors during COVID-19 infection , 2021, Computational and Structural Biotechnology Journal.
[33] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.
[34] S. Perlman,et al. SARS-CoV-2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. , 2020, The Journal of infectious diseases.
[35] P. Nigrovic. COVID-19 cytokine storm: what is in a name? , 2020, Annals of the Rheumatic Diseases.
[36] N. Alajez,et al. Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19 , 2020, Cells.
[37] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[38] J. Soriano,et al. COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes. , 2020, The Journal of clinical investigation.
[39] Madeleine K. D. Scott,et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.
[40] A. Iwasaki,et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.
[41] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[42] T. Woodruff,et al. COVID-19: Complement, Coagulation, and Collateral Damage , 2020, The Journal of Immunology.
[43] Vineet D. Menachery,et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures , 2020, Journal of Virology.
[44] Y. Marie,et al. Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity , 2020, Nature Cell Biology.
[45] G. Gao,et al. Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients , 2020, Immunity.
[46] Zhihua Zheng,et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients , 2020, Cell Host & Microbe.
[47] Nicolas Carlier,et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.
[48] C. Dooms,et al. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages , 2020, Cell Research.
[49] A. Chauhan,et al. COVID‐19: A collision of complement, coagulation and inflammatory pathways , 2020, Journal of Thrombosis and Haemostasis.
[50] Pratik Sinha,et al. Is a "Cytokine Storm" Relevant to COVID-19? , 2020, JAMA internal medicine.
[51] Roland Eils,et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.
[52] S. Heyman,et al. The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe? , 2020, Frontiers in Immunology.
[53] Eric Song,et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, bioRxiv.
[54] G. Remuzzi,et al. The case of complement activation in COVID-19 multiorgan impact , 2020, Kidney International.
[55] Lin Cheng,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[56] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[57] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[58] Mandeep R. Mehra,et al. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.
[59] C. Mummery,et al. Generation and Functional Characterization of Monocytes and Macrophages Derived from Human Induced Pluripotent Stem Cells , 2020, Current protocols in stem cell biology.
[60] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[61] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[62] F. Barrat,et al. Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types? , 2019, Current opinion in rheumatology.
[63] David K. Meyerholz,et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. , 2019, The Journal of clinical investigation.
[64] L. Su,et al. A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection. , 2019, The Journal of experimental medicine.
[65] P. Auluck,et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus , 2019, The Journal of clinical investigation.
[66] B. Reizis. Plasmacytoid Dendritic Cells: Development, Regulation, and Function , 2019, Immunity.
[67] Eugenia G. Giannopoulou,et al. Type I IFNs and TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation , 2017, Nature Immunology.
[68] Taeg S. Kim,et al. Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells , 2017, PLoS pathogens.
[69] Meredith O'Keeffe,et al. Plasmacytoid dendritic cells are short-lived: reappraising the influence of migration, genetic factors and activation on estimation of lifespan , 2016, Scientific Reports.
[70] David K. Meyerholz,et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.
[71] R. König,et al. High Secretion of Interferons by Human Plasmacytoid Dendritic Cells upon Recognition of Middle East Respiratory Syndrome Coronavirus , 2015, Journal of Virology.
[72] Eugenia G. Giannopoulou,et al. Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. , 2013, Immunity.
[73] L. Ivashkiv,et al. Regulation of type I interferon responses , 2013, Nature Reviews Immunology.
[74] W. Reith,et al. Plasmacytoid dendritic cells control T-cell response to chronic viral infection , 2012, Proceedings of the National Academy of Sciences.
[75] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[76] P. Giresi,et al. Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA , 2012, Nature Protocols.
[77] Sung Whan Cho,et al. Alveolar Macrophages Are Indispensable for Controlling Influenza Viruses in Lungs of Pigs , 2008, Journal of Virology.
[78] R. Coffman,et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation , 2008, The Journal of experimental medicine.
[79] S. Akira,et al. Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon , 2007, Blood.
[80] David E. Swayne,et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus , 2006, Nature.
[81] R. Coffman,et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation , 2006, The Journal of experimental medicine.
[82] W. Cao,et al. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. , 2006, Blood.
[83] C. Sousa. Faculty Opinions recommendation of Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. , 2005 .
[84] A. Al-ghonaium,et al. Human TLR-7-, -8-, and -9-Mediated Induction of IFN-α/β and -λ Is IRAK-4 Dependent and Redundant for Protective Immunity to Viruses , 2005, Immunity.
[85] S. Akira,et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.
[86] J. Mascola,et al. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells , 2005, The Journal of experimental medicine.
[87] F. Gheyas,et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. , 2001, Blood.
[88] N. Kadowaki,et al. The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.